Why the study?
Does intravenous fentanyl improve refractory dyspnea in an end-stage heart failure patient with renal insufficiency?
Does intravenous fentanyl improve refractory dyspnea in an end-stage heart failure patient with renal insufficiency?
Intravenous fentanyl may be an effective alternative to morphine for palliating refractory dyspnea in end-stage heart failure patients with renal insufficiency.
May relieve dyspnea in renal-impaired end-stage HF when morphine is contraindicated; hypothesis-generating, requiring prospective trials before adoption.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Ohmori et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: